Pancreatic Cancer Breakthrough: Spanish Scientists Achieve Pancreatic Tumour Regression Using CNIO Triple Therapy

The Devastating Impact of Pancreatic Cancer in Europe

Pancreatic cancer remains one of the most formidable challenges in oncology across Europe, claiming thousands of lives annually due to its aggressive nature and late-stage diagnosis. Pancreatic ductal adenocarcinoma (PDAC), the predominant form accounting for over 90% of cases, is driven by mutations in the KRAS oncogene in nearly all instances. In Spain alone, more than 10,300 new cases are diagnosed each year, contributing to Europe's broader burden where survival rates hover around 9% at five years. Late detection, coupled with rapid development of treatment resistance, underscores the urgent need for innovative therapies.

European countries face varying incidence rates, with higher occurrences in Northern Europe, yet uniformly dismal prognoses. The dense fibrotic stroma surrounding PDAC tumors further complicates drug delivery, shielding cancer cells from conventional chemotherapies like gemcitabine. This backdrop highlights why breakthroughs from leading research hubs like Spain's CNIO are met with such enthusiasm among the medical community.

CNIO Researchers Unveil Triple Therapy Mechanism

At the forefront of this advancement stands the Spanish National Cancer Research Centre (CNIO) in Madrid, where Dr. Mariano Barbacid's Experimental Oncology Group has pioneered a triple combination therapy. Published in the prestigious Proceedings of the National Academy of Sciences (PNAS) in December 2025, the study details how this regimen achieves complete pancreatic tumour regression in preclinical models.

The therapy synergistically targets the KRAS signalling pathway at three critical nodes, preventing the adaptive resistance that plagues single-agent inhibitors. First, daraxonrasib (also known as RMC-6236), an experimental pan-KRAS inhibitor currently in clinical trials for other cancers, directly blocks the mutated KRAS protein. Second, afatinib, an approved irreversible inhibitor of the EGFR/HER2 family already used in non-small cell lung cancer (NSCLC), intercepts downstream signalling. Third, SD36, a selective STAT3 protein degrader, dismantles another escape route for tumour survival.

Step-by-Step Breakdown of the Triple Therapy Process

Understanding the therapy's efficacy requires unpacking its multi-pronged attack:

• KRAS Inhibition with Daraxonrasib: This small-molecule inhibitor binds to the switch-II pocket of KRAS(G12D) and KRAS(G12V), the most common mutants in PDAC, halting GTPase-independent activation and downstream proliferation signals.
• EGFR/HER2 Blockade via Afatinib: By covalently binding to EGFR and HER2 kinases, afatinib prevents reactivation of the MAPK/ERK pathway, a frequent bypass mechanism when KRAS is inhibited alone.
• STAT3 Degradation by SD36: This targeted degrader promotes ubiquitination and proteasomal breakdown of STAT3, disrupting inflammation-driven survival and immune evasion in the tumour microenvironment.

Together, these agents create an impenetrable barrier, akin to securing a structural beam at multiple points to prevent collapse. In mouse models, tumours not only shrank but vanished entirely, with no detectable recurrence over extended observation periods.

Impressive Results Across Diverse Mouse Models

The study's rigor is evident in its use of three distinct PDAC mouse models, mirroring human disease complexity:

• Genetically engineered mice (Kras;Trp53 models) recapitulating spontaneous tumour formation.
• Orthotopic xenografts from patient-derived PDAC tissue, preserving stromal architecture.
• Surgically implanted cell-line derived tumours for rapid efficacy assessment.

In all cases, the triple therapy induced robust regression, with 100% tumour elimination and negligible toxicity. Unlike monotherapy, where resistance emerges within months, no relapse was observed, marking a paradigm shift. These findings, detailed in PNIO's peer-reviewed paper, validate the approach's translational potential. For those pursuing oncology research careers, institutions like CNIO exemplify Europe's commitment to cutting-edge science—check out research jobs in higher education for similar opportunities.

Overcoming Resistance: Why Triple Therapy Succeeds Where Others Fail

PDAC's hallmark is its plasticity—cancer cells reroute signals via parallel pathways when one is blocked. Single KRAS inhibitors, though revolutionary for lung cancers, falter in PDAC due to feedback activation of EGFR and STAT3. The CNIO strategy preempts this by simultaneous blockade, ensuring no viable escape. Preclinical data showed monotherapy tumour persistence at 50-70%, dual therapy partial control, but triple achieving zero residual disease.

This multi-targeting echoes successes in other cancers, like BRAF/MEK/EGFR triples in melanoma. For European researchers, this underscores the value of interdisciplinary collaboration; CNIO's work, funded by ERC and NextGenerationEU, highlights funding avenues for ambitious projects. Aspiring academics can prepare with resources like our guide to writing a winning academic CV.

Spotlight on Dr. Mariano Barbacid and the CNIO Team

Dr. Mariano Barbacid, a luminary in oncogene research since discovering RAS in the 1980s, leads this effort alongside co-lead Carmen Guerra and first authors Vasiliki Liaki and Sara Barrambana. CNIO, Spain's premier cancer institute, fosters a vibrant ecosystem linking basic science to clinical translation, often partnering with universities like Universidad Complutense de Madrid.

The team's persistence over six years exemplifies the rigour of European higher education research. Barbacid cautions, "We are not yet ready for clinical trials," emphasizing the translational hurdles ahead. Yet, this positions CNIO as a hub for talent, offering postdoctoral fellowships and group leader roles—ideal for PhDs eyeing postdoc positions in Europe.

Patient Implications and European Healthcare Context

For Europe's 100,000+ annual PDAC patients, this heralds cautious optimism. Current standards—surgery for 20%, FOLFIRINOX chemo for fit patients—yield median survival of 12-24 months. Triple therapy could extend this dramatically if translatable, potentially shifting PDAC from terminal to manageable.

Spain's national health system (SNS) and EU-wide initiatives like Mission Cancer prioritize such innovations. Early detection via AI-risk models, combined with targeted therapies, could amplify impact. Stakeholders, from patient advocacy groups to policymakers, advocate accelerated trials.

Challenges Ahead: From Bench to Bedside

Translating mouse success to humans demands overcoming pharmacokinetics, dosing optimization, and patient heterogeneity. Daraxonrasib enters phase 3 for NSCLC (NCT06625320), afatinib is approved, but SD36 requires further validation. Toxicity profiles, while favourable in mice, need human scrutiny.

Regulatory paths via EMA will scrutinize combinations. CNIO's blueprint guides pharma partners, but timelines stretch 5-10 years. Researchers navigating this can benefit from Europe higher ed jobs in clinical research.

Broader Ripple Effects on European Cancer Research

This breakthrough invigorates Europe's oncology ecosystem, from UKRI-funded consortia to Horizon Europe grants. It validates KRAS as druggable in solid tumours, spurring investments. Universities across Spain, Germany, and France now prioritize pathway inhibitors.

For academics, it signals demand for expertise in degraders and multi-omics—fields ripe for clinical research jobs.

Career Opportunities in Oncology Research Across Europe

The CNIO model attracts global talent via 'CNIO Friends' postdoc contracts and internships. Spain's biotech boom, bolstered by EU funds, offers lecturer and professor roles in tumour biology. Explore professor jobs or lecturer jobs to contribute.

With rising needs, platforms like AcademicJobs.com connect talents to higher ed jobs.

Photo by Luli Sosa Benintende on Unsplash

Future Outlook: Towards Clinical Reality

Optimism tempers realism—phase 1 trials could launch by 2028, per experts. Combined with immunotherapy and stroma modifiers, cures loom. For patients, join trials via EORTC; for researchers, seize this momentum. Stay informed and engaged with Rate My Professor, higher ed career advice, and university jobs.